Advert - Britannia Pharmaceuticals Ltd – Case AUTH/3355/5/20

Conduct in relation to payments to health professionals, meetings in India, alleged failure to disclose information to the PMCPA and investigator led clinical trials

For paying health professionals for the preparation time when this was not warranted nor required as the same material or essentially the same material was reused by speakers, not having a contract for some of the engagements, not providing full information to the PMCPA about the arrangements for speakers at meetings outside the UK and arrangements for investigator led clinical trials which failed to consider patient safety and have the relevant approval processes in place, Britannia was ruled in breach of the following clauses of the 2019 Code:


Clause 2           - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry

Clause 9.1        - Failing to maintain high standards

Clause 13.4      - Failing to comply with the requirements for non-interventional studies

Clause 18.1      - Paying health professionals fees which did not reflect fair market value

Clause 23.1      - Engaging health professionals in other than genuine consultancy arrangements

Clause 25.2      - Failure to approve and supervise non interventional studies


In addition the Code of Practice Appeal Board required Britannia to be audited.